Evidence map›Paper›PMID 26097803›Full record

ArticleIntensive care medicine experimental2015

Raxibacumab augments hemodynamic support and improves outcomes during shock with B. anthracis edema toxin alone or together with lethal toxin in canines.

Kenneth E Remy, Xizhong Cui, Yan Li, Junfeng Sun, Steven B Solomon, Yvonne Fitz, Amisha V Barochia, Mariam Al-Hamad, Mahtab Moayeri, Stephen H Leppla and 1 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Intensive care medicine experimental, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.8field-weighted citation impact, top 28% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 8 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Kenneth E RemyCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. kenneth.remy@mail.nih.gov.
Xizhong CuiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. CXizhong@cc.nih.gov.
Yan LiCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. yli3@cc.nih.gov.
Junfeng SunCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. junfeng.sun@nih.gov.
Steven B SolomonCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. SSolomon@cc.nih.gov.
Yvonne FitzCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. YFitz@cc.nih.gov.
Amisha V BarochiaNational Heart, Lung and Blood Institute, National Institutes of Health, Bethesda, MD, USA. barochiaav@nhlbi.nih.gov.
Mariam Al-HamadCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. mariam.alhamad@gmail.com.
Mahtab MoayeriNational Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. mmoayeri@niaid.nih.gov.
Stephen H LepplaNational Institute of Allergy and Infectious Disease, National Institutes of Health, Bethesda, MD, USA. sleppla@niaid.nih.go.
Peter Q EichackerCritical Care Medicine Department, Clinical Center, National Institutes of Health, Bldg 10, Rm 2C145, Bethesda, MD, 20892, USA. PEichacker@cc.nih.gov.
National Institutes of Health Clinical Center · USNational Institutes of Health · USNational Institute of Allergy and Infectious Diseases · US

Funding

Pathophysiological Actions of the Anthrax ToxinsZIAAI001032 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI LEPPLA, STEPHEN · 2009 to 2025
$10.9M
Hemodynamic and anti-Toxin Treatments in Anthrax Lethal Toxin Challenged CaninesZIACL090024 · CLC · CLINICAL CENTER · PI EICHACKER, PETER · 2010 to 2016
$0k
Intramural NIH HHS Z99 CL999999
6 · The paper itself

Abstract

backgroundLethal and edema toxin contribute to shock and lethality with Bacillus anthracis. We showed previously in a 96-h sedated canine model that raxibacumab, a monoclonal antibody against protective antigen, augmented hemodynamic support (HS) and improved survival with lethal toxin challenge. Here we study raxibacumab further. Using this model, we have now studied raxibacumab with 24 h edema toxin challenges (Study 1), and lethal and edema toxin challenges together (Study 2).

methodsUsing our canine model, we have now studied raxibacumab with 24h edema toxin challenges (Study-1), and lethal and edema toxin challenges together (Study-2).

resultsIn Study 1, compared to no treatment, HS (titrated fluid and norepinephrine) increased mean arterial blood pressure (MAP, p ≤ 0.05) but not survival [0 of 10 (0/10) animals survived in each group] or median survival time [43.8 h (range 16.8 to 80.3) vs. 45.2 h (21.0 to 57.1)]. Compared to HS, HS with raxibacumab treatment at or 6 h after the beginning of edema toxin increased MAP and survival rate (6/7 and 7/8, respectively) and time [96.0 h (39.5 to 96.0) and 96.0 h (89.5 to 96.0), respectively]; (p ≤ 0.05). HS with raxibacumab at 12 h increased MAP (p ≤ 0.05) but not survival [1/5; 55.3 h (12.6 to 96.0)]. In Study-2, survival rate and time increased with HS and raxibacumab at 0 h (4/4) or 6 h after (3/3) beginning lethal and edema toxin compared to HS [0/5; 71.5 h (65 to 93)] (p = 0.01 averaged over raxibacumab groups).

conclusionsRaxibacumab augments HS and improves survival during shock with lethal and edema toxin.

Indexed as

B. anthracisEdema toxinLethal toxinMonoclonal antibodyProtective antigenRaxibacumab

Identifiers

PMID26097803
PMCPMC4473792
OpenAlexW2162355024

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.